Data from the MONARCH2, PALOMA-1, and TREnd trials strongly support using CDK4/6 inhibitors alongside standard endocrine therapy for advanced ER-positive breast cancer. Including these targeted agents not only improves progression-free survival but may reverse acquired resistance to hormone treatment.
http://ift.tt/2w1slLJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου